Made With Uberflip Content Marketing

Youtube - All Videos

Videos from EBD Group series of life science partnering events and interviews with key opinion leaders across pharma, biotech and investment.

  • Biotech Showcase™ 2017: Catabasis pursues bifunctional mutation-agnostic approach to DMD7:09

    Biotech Showcase™ 2017: Catabasis pursues bifunctional mutation-agnostic approach to DMD

    Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified an NF-κB inhibitor—edasalonexent—as a potential Duchenne muscular dystrophy (DMD) treatment. Spea

    Watch Video
  • Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry8:15

    Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry

    With the Chinese market growing at 10–15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-founder and managing partner at consultants TPP Healthcare, explains to Mike Ward, global dir

    Watch Video
  • Biotech Showcase™ 2017: Advancing neurokinin receptor antagonists in respiratory and women’s health6:18

    Biotech Showcase™ 2017: Advancing neurokinin receptor antagonists in respiratory and women’s health

    Starting the year with a cash injection of GDP 23 million, 2012 GSK spin-out NeRRe Therapeutics intends to advance its neurokinin receptor antagonist pipeline towards late-stage clinical development.

    Watch Video
  • Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets6:07

    Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets

    Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking to add three to four more assets to its portfolio. Company founder and CEO, Denis Corin, outli

    Watch Video
  • Biotech Showcase™ 2017: AmpliPhi advances phage in clinic to address microbial infections8:31

    Biotech Showcase™ 2017: AmpliPhi advances phage in clinic to address microbial infections

    Using cocktails of bacteriophages to attack bacterial infections, San Diego-based AmpliPhi announced progress in Phase I studies of its lead program. Company CEO Scott Salka explains to Mike Ward, Inf

    Watch Video
  • Biotech Showcase™ 2017: Refocusing Tarveda on tumor-targeted mini-drug conjugates5:58

    Biotech Showcase™ 2017: Refocusing Tarveda on tumor-targeted mini-drug conjugates

    In the past 18 months, Tarveda Therapeutics has been refocusing its efforts on Pentarins, its miniaturized drug conjugates, designed to target, penetrate and eradicate solid tumors. Having raised USD

    Watch Video
  • Biotech Showcase™ 2017: Shield pilots ironclad specialty future with Feraccru8:06

    Biotech Showcase™ 2017: Shield pilots ironclad specialty future with Feraccru

    Bolstered with a successful launch in Germany and the UK of its anemia treatment Feraccru, Shield Therapeutics is looking to expand both the label and its market reach. Co-Founder and CEO Carl Sterrit

    Watch Video
  • Biotech Showcase™ 2017: Rexgenero readies cell therapy for Critical Limb Ischemia Phase III6:16

    Biotech Showcase™ 2017: Rexgenero readies cell therapy for Critical Limb Ischemia Phase III

    Founded as recently as 2014, Rexgenero is poised to start two Phase III trials of its lead candidate Rexmyelocel-T (REX-001) in patients with Critical Limb Ischemia. CEO Dr. Joe Dupere tells Mike Ward

    Watch Video
  • Biotech Showcase™ 2017: Keryx looks to label expansion to drive Auryxia9:45

    Biotech Showcase™ 2017: Keryx looks to label expansion to drive Auryxia

    After a stuttering launch and relaunch, Keryx Biopharmaceuticals CEO Greg Madison revealed to Mike Ward, Informa Pharma Intelligence’s insights global director of content, that Auryxia prescriptions p

    Watch Video
  • Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients7:53

    Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients

    Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duvall, newly appointed CEO of San Diego-based gene therapy technology company Tocagen, tells Mik

    Watch Video
  • Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 20174:24

    Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017

    An increased focus on the need to access and develop truly transformational medicines was a key theme in the hallway chatter at this year’s Biotech Showcase/JP Morgan Healthcare meetings. Michael Hay,

    Watch Video
  • Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception9:11

    Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception

    With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism, has plenty of reasons for insomnia

    Watch Video
  • Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America8:28

    Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America

    As Johnson & Johnson announced the establishment of its eighth JLABS facility, in collaboration with New York State and the New York Genome Center, Melinda Richter, head of Johnson & Johnson Innovatio

    Watch Video
  • Biotech Showcase™ 2017: Reinventing Arena to focus on Phase II clinical candidates6:06

    Biotech Showcase™ 2017: Reinventing Arena to focus on Phase II clinical candidates

    In the six months after joining Arena Pharmaceuticals as CEO, Dr. Amit Munshi has been busy: reducing the company’s commitment to obesity drug Belviq, which it has partnered with Eisai; spinning out t

    Watch Video
  • Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology10:37

    Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology

    Sierra Oncology president and CEO Dr. Nick Glover tells Mike Ward, Informa Pharma Intelligence insight global director of content, how the company is rebranding itself from its former incarnation ProN

    Watch Video
  • Biotech Showcase™ 2017: PhaseRx makes more noise than silence with mRNA delivery8:05

    Biotech Showcase™ 2017: PhaseRx makes more noise than silence with mRNA delivery

    Having ditched RNA silencing in 2012, PhaseRx president and CEO Dr. Robert Overell explains to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how delivering

    Watch Video
  • Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery8:05

    Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery

    Microbiome discovery and development will trigger the next major paradigm shift in medicine, more profound than the discovery of recombinant DNA, Second Genome CEO Glenn Nedwin predicted in an intervi

    Watch Video
  • Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity9:36

    Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity

    Cellular Biomedicine Group (CBMG) CEO Bizuo (Tony) Liu differentiates plans for chimeric antigen receptor-T cell development in part by large-scale production in the company's home country, China. In

    Watch Video
  • Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML12:05

    Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML

    Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the tough-to-treat acute myeloid leukemia (AML), MEI Pharma CEO Dan Gold says he is optimistic hea

    Watch Video
  • Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta10:13

    Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta

    Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 2016, Flexion Therapeutics CEO Mike Clayman is hoping for priority review of the filing, in add

    Watch Video
  • loading
    Loading More...